High-dose regimen of cancer drug reduces MS disease activity.
A small, uncontrolled clinical trial in nine people with
relapsing-remitting MS suggests that a regimen of high-dose chemotherapy high-dose chemotherapy Oncology The administration of chemotherapeutics in excess of BM toxicity; given the risk of aplastic anemia, HDC requires autologous BMT and use of 'rescue' factors such as G-CSF, GM-CSF, and erythropoietin. See Bone marrow transplantation. (IV cyclophosphamide cyclophosphamide /cy·clo·phos·pha·mide/ (-fos´fah-mid) a cytotoxic alkylating agent of the nitrogen mustard group; used as an antineoplastic, as an immunosuppressant to prevent transplant rejection, and to treat some diseases ) significantly reduced disability and MRI-detected
disease activity in most, and resulted in sustained remission in some;
they had been followed for an average of 23 months. Larger, controlled
trials are needed. The study, by Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. researchers,
was funded in part by the National MS Society.
COPYRIGHT 2008 National Multiple Sclerosis Society
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion